Ligand Pharmaceuticals LGND Finance Lease Liabilities (Total)
Finance Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The official record: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's finance lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's finance lease liabilities (total)?
- Ligand Pharmaceuticals (LGND) reported finance lease liabilities (total) of $50K in Q4 2025.
- How has Ligand Pharmaceuticals's finance lease liabilities (total) changed year-over-year?
- Ligand Pharmaceuticals's finance lease liabilities (total) decreased by 31.5% year-over-year, from $73K to $50K.
- What is the long-term trend for Ligand Pharmaceuticals's finance lease liabilities (total)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's finance lease liabilities (total) has grown at a -62.5% compound annual growth rate (CAGR), from $6.71M to $50K.
- What does finance lease liabilities (total) mean?
- Finance lease liabilities (total) represent the aggregate present value of all future lease payments for assets where the company assumes substantially all risks and rewards of ownership. This metric reflects the long-term debt-like burden associated with financing infrastructure or equipment through leases. It is a key component of the company's total leverage profile.